Dementia, Alzheimer's disease, Internal medicine, Psychiatry and Disease are his primary areas of study. The Dementia study combines topics in areas such as Cognition, Gerontology and Activities of daily living. His Alzheimer's disease research incorporates themes from Central nervous system disease, Neuroscience, Degenerative disease, Pediatrics and Cognitive disorder.
His studies in Internal medicine integrate themes in fields like Placebo, Irritability, Surgery and Endocrinology. His work deals with themes such as Memantine, Clinical trial and Clinical psychology, which intersect with Psychiatry. His Disease research also works with subjects such as
His main research concerns Disease, Dementia, Internal medicine, Alzheimer's disease and Psychiatry. His study looks at the relationship between Disease and topics such as Neuroscience, which overlap with Amyloid. His studies deal with areas such as Cognition, Gerontology and Clinical psychology as well as Dementia.
His Internal medicine study which covers Oncology that intersects with Biomarker. His research integrates issues of Central nervous system disease and Degenerative disease in his study of Alzheimer's disease. His research on Psychiatry frequently connects to adjacent areas such as MEDLINE.
Serge Gauthier mainly investigates Disease, Dementia, Internal medicine, Neuroimaging and Neuroscience. As part of one scientific family, Serge Gauthier deals mainly with the area of Disease, narrowing it down to issues related to the Cohort, and often Alzheimer's disease. Serge Gauthier studies Dementia, namely Cognitive decline.
The Internal medicine study which covers Magnetic resonance imaging that intersects with Cardiology. His Neuroimaging research is multidisciplinary, incorporating elements of Disease progression and Atrophy. His Neuroscience research incorporates elements of Neuroinflammation, Frontotemporal dementia and Disease spectrum.
The scientist’s investigation covers issues in Dementia, Disease, Internal medicine, Cognition and Cognitive decline. His study in Dementia focuses on Frontotemporal dementia in particular. His study in Disease is interdisciplinary in nature, drawing from both Neurology, Cohort and Intensive care medicine.
His Cohort research includes themes of Alzheimer's disease, Mild memory loss, Population ageing and Gerontology. His Internal medicine study incorporates themes from Standardized uptake value, Magnetic resonance imaging and Oncology. Serge Gauthier interconnects Telemedicine, Telehealth, Applied psychology and Best practice in the investigation of issues within Cognition.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium
I. G. McKeith;I. G. McKeith;D. W. Dickson;J. Lowe;M. Emre.
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Bruno Dubois;Howard H. Feldman;Claudia Jacova;Steven T. DeKosky.
Lancet Neurology (2007)
Mild cognitive impairment
Serge Gauthier;Barry Reisberg;Michael Zaudig;Ronald C. Petersen.
The Lancet (2006)
Clinical diagnostic criteria for dementia associated with Parkinson's disease.
Murat Emre;Dag Aarsland;Dag Aarsland;Richard Brown;David J. Burn.
Movement Disorders (2007)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel.
Lancet Neurology (2014)
Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois;Howard H. Feldman;Howard H. Feldman;Howard H. Feldman;Claudia Jacova;Jeffrey L. Cummings.
Lancet Neurology (2010)
Vascular Cognitive Impairment
John T O'Brien;Timo Erkinjuntti;Barry Reisberg;Gustavo Roman.
Clive Ballard;Serge Gauthier;Anne Corbett;Carol Brayne.
Prevalence and severity of cognitive impairment with and without dementia in an elderly population
Janice E Graham;Kenneth Rockwood;B Lynn Beattie;Robin Eastwood.
The Lancet (1997)
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Michael Rösler;Ravi Anand;Ana Cicin-Sain;Serge Gauthier.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: